MBX Biosciences is trading at $52.00, down 4.66%, amid biotech-sector and broader market pressure. - During the October 8 session, no new company-specific announcement explaining the decline was found. - The biotech sector was also under pressure, with XBI down 2.04% in the regular session. - Reuters reported Brent jumped over 4% and the 10-year yield climbed to 5.34%; available evidence points to sector and market pressure, not a company-specific catalyst.